Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates
Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.
Ensemble Therapeutics is eligible to receive payments and may receive up to $186 million in success milestones in case of full commercial success of multiple drug products, including an upfront payment and research funding. In addition, Ensemble Therapeutics is eligible to receive royalties on future sales of products that arise from the collaboration. Further details of the agreement were not disclosed.
The collaboration will deploy Ensemble Therapeutics' proprietary drug discovery platforms including its Ensemblin collection of about 5 million macrocycles to discover and advance novel drug candidates against Boehringer Ingelheim's drug targets. Boehringer Ingelheim will have the exclusive right to develop and commercialize substances arising from the collaboration.
"This collaboration with Boehringer Ingelheim builds on Ensemble's business strategy to partner with leading pharmaceutical companies and further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional funding to advance our own internal pipeline," said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.